Stock Track | Novavax Plummets 5.19% Amid Broader Vaccine Market Sell-Off

Stock Track
01-08

Novavax Inc., a biotechnology company that develops vaccines for serious infectious diseases, saw its stock plummet 5.19% during intraday trading on Wednesday. This decline comes despite an initial premarket rally spurred by the recent CDC report on rising COVID-19 and flu cases across the United States.

The sell-off in Novavax's shares seems to be part of a broader market correction in the vaccine sector. Major vaccine makers like Moderna, Novo Nordisk, CureVac, and BioNTech, which initially rallied on the CDC's respiratory illness data, also experienced a pullback during intraday trading.

While the CDC's warning of increased COVID-19 and flu activity initially boosted investor confidence in vaccine manufacturers, it appears that the market has now priced in this news, leading to profit-taking and a subsequent decline in stock prices for companies like Novavax.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10